As the midterm elections approach, with the trajectory pointing toward increasing likelihood of the Democrats taking control of the House of Representatives and with each Trump tweet on drug pricing, a feeling of foreboding has settled over the pharmaceutical industry.
How Katherine High, M.D., cofounder, president, and head of R&D at Spark Therapeutics, helped reinvigorate the life sciences industry’s interest in gene therapy.
Don DeGolyer talks about the process he took to go from working at a Big Pharma like Sandoz to founding and running his own small specialty pharma company.
To maintain your market exclusivity against generic competition, you need to understand how your actions may potentially affect patent coverage and enforcement.
There has to be a better way of successfully bringing newer classes of drugs to market and sustainably scaling innovation. The low rate of success and economic burden it places on companies and payers is not sustainable and screams for alternate commercialization models.
Lou Schmukler, president of global product development and supply at Bristol-Myers Squibb, explains some of the nuances between small and large molecule drug manufacturing.
Tony Coles, M.D., former CEO of Onyx Pharmaceuticals, provides his perspective on Amgen’s $9.7 billion acquisition of Onyx.
Tony Coles, M.D., chairman and CEO of Yumanity Therapeutics, discusses the decision to acquire Proteolix for $800 million when serving as the CEO of Onyx Pharmaceuticals.